Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis
Public ClinicalTrials.gov record NCT00004736. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Viral and Immune Dynamics in HIV-Infected Patients With Tuberculosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to see if a type of anti-HIV therapy called HAART is effective in lowering levels of HIV and boosting the immune system in HIV-infected patients with tuberculosis (TB). HIV-infected patients with TB have higher levels of HIV and lower CD4 cell counts (cells in the body that fight infection) than HIV-infected patients without TB. HAART has been effective in reducing HIV levels and increasing CD4 cells in patients without TB. However, its effects in HIV-infected patients with TB are unknown.
Study identification
- NCT ID
- NCT00004736
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 44 participants
Conditions and interventions
Conditions
Interventions
- Nelfinavir mesylate Drug
- Ethambutol hydrochloride Drug
- Isoniazid Drug
- Pyrazinamide Drug
- Lamivudine Drug
- Rifabutin Drug
- Stavudine Drug
- Zidovudine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Not listed
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Sep 10, 2008
United States locations
- U.S. sites
- 10
- U.S. states
- 6
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Univ of Southern California / LA County USC Med Ctr | Los Angeles | California | 900331079 | — |
| Univ of California / San Diego Treatment Ctr | San Diego | California | 921036325 | — |
| Cook County Hosp | Chicago | Illinois | 60612 | — |
| Beth Israel Med Ctr | New York | New York | 10003 | — |
| Bellevue Hosp / New York Univ Med Ctr | New York | New York | 10016 | — |
| Columbia Presbyterian Med Ctr | New York | New York | 10032 | — |
| Univ of Pennsylvania at Philadelphia | Philadelphia | Pennsylvania | 19104 | — |
| Brown Univ / Miriam Hosp | Providence | Rhode Island | 02906 | — |
| Miriam Hosp / Brown Univ | Providence | Rhode Island | 02906 | — |
| Vanderbilt Univ Med Ctr | Nashville | Tennessee | 37203 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00004736, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 10, 2008 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00004736 live on ClinicalTrials.gov.